Ranbaxy gets nod to launch ulcer generic drug in US

Ranbaxy Laboratories has received the final approval from the USFDA to make and sell the generic version of Sciele Pharma’s peptic ulcer tablet Robinul for 1 mg and 2 mg dosages.

By ET Bureau | Aug 25, 2009, 05.47 AM IST

NEW DELHI: Drugmaker Ranbaxy Laboratories has received the final approval from the US Food and Drug Administration (USFDA) to make and sell the generic version of Sciele Pharma��s peptic ulcer tablet Robinul for 1 mg and 2 mg dosages.

The annual market sales of Robinul is $26 million in the US, Ranbaxy said in a statement. Ranbaxy, now owned by Japan��s Daiichi Sankyo, plans to launch the tablet during the December quarter.

Start a SIP with as low as ₹500 with ET Money App!